Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9UZ5Q
|
|||
| Drug Name |
NC318
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 2 | [1] | |
| Company |
NextCure
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04699123) The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of NextCure. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.